Abstract: Disclosed are novel bioabsorbable and biodegradable monomer compounds, bioabsorbable and biodegradable polymers therefrom, and methods of making such monomers and polymers, which are useful in pharmaceutical delivery systems, tissue engineering applications, tissue adhesives products, implantable medical devices, foams and reticulated foams for wound healing and drug delivery, bone hemostats and bone void fillers, adhesion prevention barriers, meshes, filters, stents, medical device coatings, pharmaceutical drug formulations, consumer product and cosmetic and pharmaceutical packaging, apparel, infusion devices, blood collection tubes and devices, other medical tubes, skin care products, and transdermal drug delivery materials.

Abstract: The present invention provides processes for the preparation of crystalline forms of Tigecycline.

Abstract: This invention is directed to novel aryl sulfonamide and sulfamide compounds which bind selectively to and inhibit the activity of the human Y5 receptor. This invention is also related to uses of these compounds for the treatment of feeding disorders such as obesity, anorexia nervosa, bulimia nervosa, and abnormal conditions such as sexual/reproductive disorders, depression, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure or sleep disturbances and for the treatment of any disease in which antagonism of a Y5 receptor may be useful.

Abstract: The invention relates to new pharmaceutically active compounds which are are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.

Abstract: Novel chemical compounds and mixtures of same are provided having antibacterial and other utilities. The mixtures preferably are formed by reacting a cyclic scaffold moiety with a set of chemical substituients. Libraries formed in accordance with the invention have utility per se and are articles of commerce. They can be used to screen for pesticides, drugs and other biologically active compounds.

Abstract: The present invention provides a pharmaceutical composition for local administration in the form of an emulsion that contains active vitamin D3 and is suitable for application to areas with (the) hair, while also having satisfactory pharmacological activity, primary drug stability and physical stability. This lotion contains (a) a therapeutically effective amount of active vitamin D3, (b) an oil phase component containing a solid oil component comprising white Petrolatum and a higher alcohol and a liquid oil component comprising squalane, (c) an aqueous phase component containing ionic polysaccharide, and (d) nonionic surfactant; wherein, (1) the content of said ionic polysaccharide is 0.3-1.0 parts by weight of the entire preparation, (2) the content of said higher alcohol is 0.2-1.0 parts by weight of the entire preparation, and (3) the HLB of said nonionic surfactant is 10 or more.

Abstract: The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.

Abstract: Multiple reaction schemes, process steps and intermediates are provided for the synthesis of epoxymexrenone, useful as a diuretic, and other compounds of Formula I wherein the variables are as defined by the specification.

Abstract: Compounds of formula (I) in which the radicals are as defined in the specification and claims, and physiologically tolerated and physiologically functional derivatives thereof and processes for their preparation are described. The compounds are suitable, for example, as hypolipidemic agents.

Abstract: The invention is directed to compounds, compositions and method of preparation of compounds of formulae I and II: wherein X, Q1, Q2, R1 and R2 are as defined by the specification. The compounds are disclosed as useful cholesterol-lowering and anti-atherosclerosis agents.

Abstract: 3-Oxyiminopregnane-21-carbolactones of formula I, wherein R is as defined by the specification, their production and use as pharmaceutical agents are described.

Abstract: Compositions of non-steroidal glucocorticoid antagonists for treating glaucoma or ocular hypertension and methods for their use are disclosed.

Abstract: The present invention relates to a therapeutic composition and formulation for the treatment of viral diseases such as, Dengue fever and influenza. More particularly, to therapeutic preparation comprising substantially water soluble, local anesthetic of the ester type, procaine hydrochloride and a water soluble glucocorticoid, dexamethasone sodium phosphate.

Abstract: Described herein is a process for the preparation of an acetal of formula (I) in which R1 is an alkyl, R2 is H or an acyl, X is &bgr;-OH and Y is H, comprising the acetalization with control of the epimeric distribution at the C-22 position, for treatment with R1 CHO in aqueous HBr or HI of a compound of formula (II) in which R2 has the meaning specified above, R3 and R4 are both H, or, taken together, are —C(R5)(R6)—, where R5 and R6, which may be the same or different from one another, are alkyl groups, and X and Y are chosen from among the following: A) X and Y, taken together, are an additional bond between C-9 and C-11; B) X is &bgr;-OH, and Y is H or an &agr;-halogen; C) X is &bgr;-OR7 where R7 is an acyl, and Y is H or an &agr;-halogen; and D) X and Y, taken together, are —O—.

Abstract: This invention presents alkali metal salts of 8,9-dehydroestrone, salts of its sulfate ester, and stable compositions thereof, as well as processes for their production and use in estrogen replacement therapy and cardiovascular protection.

Abstract: Disclosed is the use of 2-oxoasiatic acid in the treatment of dementia or cognitive disorders.

Abstract: 1.alpha.,24(S)-Dihydroxy vitamin D.sub.2 which is useful as an active compound of pharmaceutical compositions for the treatment of disorders of calcium metabolism and for various skin disorders. The invention also includes preparation of synthetic 1.alpha.,24(S)-dihydroxy vitamin D.sub.2 starting from ergosterol which is converted in six steps to 24-hydroxyergosterol. 24-Hydroxyergosterol is irradiated and thermally converted to 24-hydroxy vitamin D.sub.2 which is converted in six steps to 1.alpha.,24(S)-dihydroxy vitamin D.sub.2. The syntheses also produced novel intermediates.

Abstract: Substituted phenylalkenoylguanidines, processes for their preparation, uses as medicaments or diagnostics, and medicaments containing them are described.The invention relates to substituted phenylalkenoylguanidines and their pharmaceutically tolerable salts and physiologically functional derivatives of the formula ##STR1## in which the radicals have the meanings indicated, and their physiologically tolerable salts and processes for their preparation. The compounds are suitable as medicaments for the prophylaxis or treatment of gallstones.

Abstract: The invention relates to a process for the production of 16-dehydropregnenolone acetate of the formula ##STR1## comprising the oxidation of pseudodiosgenin diacetate in the presence of a phase transfer catalyst at a temperature between 0-15.degree. C. to produce diosone followed by the hydrolysis and degradation of diosone to produce 16-dehydropregnenolone acetate.

Abstract: Compounds of formula (I) ##STR1## as defined by the specification. The compounds are useful in the treatment or prevention of vitamin D dependent disorders, particularly psoriasis, basal cell carcinomas, disorders of keratinization and keratosis, leukemia, osteoporosis, hyperparathyroidism accompanying renal failure, transplant rejection and graft vs. host disease.